A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer

Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of...

Full description

Bibliographic Details
Main Authors: Jing-Jing Wang, Michelle Kwan-Yee Siu, Yu-Xin Jiang, Thomas Ho-Yin Leung, David Wai Chan, Huo-Gang Wang, Hextan Yuen-Sheung Ngan, Karen Kar-Loen Chan
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Biomolecules
Subjects:
ovarian cancer
immunotherapy
T cells
glutamine metabolism
Online Access:https://www.mdpi.com/2218-273X/11/12/1749

Internet

https://www.mdpi.com/2218-273X/11/12/1749

Similar Items